Page last updated: 2024-11-03

risperidone and Leukemia, Myeloid, Acute

risperidone has been researched along with Leukemia, Myeloid, Acute in 1 studies

Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.

Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Vives, S1
Batlle, M1
Montané, E1
Ribera, JM1

Other Studies

1 other study available for risperidone and Leukemia, Myeloid, Acute

ArticleYear
[Rhabdomyolysis and renal failure secondary to interaction between simvastatin, ciclosporin A and risperidone in an allogeneic stem cell transplantation patient].
    Medicina clinica, 2008, Nov-15, Volume: 131, Issue:17

    Topics: Acute Kidney Injury; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Humans; Leukemia, M

2008